Given that BCL-XL inhibitors including navitoclax cause thrombocytopenia, a combination of navitoclax with AZD8055 (or another mTOR inhibitor) may not be clinically feasible [14, 15]. The gene discussed is MTOR; the disease is Thrombocytopenia.